Strategy update. Product launch in research laboratories planned for the end of 2022
By launching a product for research laboratories, Lumito enables market access by late 2022. The Company considers that there is business potential in research laboratories, which may generate sales as of 2022. In addition, it may draw media attention to the Company's technology and deepen understanding of the opportunities offered by the technology, moving forward. […]
Lumito AB publishes Quarterly Report 3, 2021
Financial overview Third quarter, January–September 2021 Net sales amounted to KSEK 0 (0). Result after taxes amounted to KSEK -19,517 (-10,848). Basic and diluted earnings per share amounted to SEK -0.22 (-0.15). Cash flow from operating activities after change in working capital amounted to KSEK -19,927 (-12,239). Cash and cash equivalents amounted to KSEK […]
Lumito AB publishes Quarterly Report 2, 2021
Financial overview of the second quarter and the half year Second quarter 2021, April 1 – June 30 Net sales amounted to KSEK 0 (0). Result after taxes amounted to KSEK -6 619 (-4 202). Earnings per share before and after dilution amounted to SEK -0.08 (-0.06). Cash flow from operating activities after changes in […]
Lumito AB publishes Quarterly Report 1, 2021
Financial overview for the first quarter January 1st to March 31st, 2021 • Net sales amounted to SEK 0 (0) thousand • Profit after tax amounted to SEK -6,825 (-2,795) thousand. • Earnings per share before and after dilution amounted to SEK -0.08 (-0.04). • Cash flow from operating activities after changes in working capital […]
Lumito publishes Year-end Report for 2020
Financial overview 2020 Financial overview of the fourth quarter, 1 October – 31 December 2020. Net sales amounted to kSEK 0 (0). Result after taxes amounted to kSEK -5,200 (-2,545). Basic and diluted earnings per share amounted to SEK -0.06 (-0.04) Cash flow from operating activities amounted to kSEK -5,198 (-3,145). Financial overview of the […]
New CEO of Lumito AB
The Board of Directors of Lumito AB has resolved to appoint Mattias Lundin CEO of the Company. He will take office on March 8, 2021. The Board of Directors of Lumito AB has resolved to appoint Mattias Lundin CEO of the Company. He will take office on March 8, 2021. Mattias Lundin is currently the […]
Lumito initiates process to engage in dialogue with future partners
The awareness about Lumito's (https://lumito.se/en/home/) potential is on the rise among companies active in digital pathology, and Lumito has received approaches from leading companies in health technologies and diagnostics. The interest in the Company demonstrates that Lumito is in just the right phase. Diagnostics is currently a bottleneck of the system. More and more laboratories abandon […]
Two European patents approved for tissue diagnostics
"Another milestone is passed as Lumito's third patent family now is granted in Europe as the first region. The patent (WO2018224688A1), ”A method of anaIysing a sampIe for at Ieast one anaIyte”, specifically contains the area of application that Lumito's first product launch is targetingand protects the Company's in vitro diagnostics based on upconversion nanoparticles (UCNP). We hope that […]
Delivery from RISE – Lumito proceeds to make optimizations on its own account
On behalf of Lumito, RISE has developed protocols for development of reagents for tissue staining based on UCNPs (UpConverting NanoParticles). The stained tissue samples are scanned with Lumitos scanner to obtain high-contrast imaging without background information. RISE delivered the results of the development effort at the end of June. During spring, Lumito has established a laboratory […]
Quarterly report 1, 2020, Lumito AB (publ).
Financial overview of the first quarter, 1 January – 31 March 2020 Result after taxes amounted to kSEK -2,795 (-1,958). Basic and diluted earnings per share amounted to SEK -0.04 (-0.08). Cash flow from operating activities amounted to kSEK -2,793 (-1,958). Cash and cash equivalents amounted to kSEK 17,675 (8,079) on the balance sheet date. […]
